Drug Combination Details
| General Information of the Combination (ID: C33678) | |||||
|---|---|---|---|---|---|
| Name | Flavopiridol NP Info | + | 4-hydroxy-tamoxifen Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Augmenting Drug Sensitivity | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP2 | Molecule Info |
Pathway MAP
|
|
| Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
||
| Biological
Regulation |
Arrest | Cell cycle arrest in G2 phase | ||||
| In-vitro Model | MON | CVCL_M846 | Extrarenal rhabdoid tumor | Homo sapiens | ||
| G-401 | CVCL_0270 | Rhabdoid tumor of the kidney | Homo sapiens | |||
| A-204 | CVCL_1058 | Embryonal rhabdomyosarcoma | Homo sapiens | |||
| Experimental
Result(s) |
Combining flavopiridol with 4OH-Tam potently inhibited the growth of RT cells by increasing the ability of either drug alone to induce caspases 2 and 3 thereby causing apoptosis. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Potent inhibition of rhabdoid tumor cells by combination of flavopiridol and 4OH-tamoxifen. BMC Cancer. 2010 Nov 19;10:634. | |||
